GlassScriptPhysician profile
Danielle Seidman
NPI 1285029710
$1,719.87
in general payments reported to CMS, 2019-2025
11 companies · $129 in 2025
The $129 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $276 · 2022: $869 · 2023: $210 · 2024: $236 · 2025: $129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $654.29 | 2022 | |
| Novartis Pharmaceuticals Corporation | $262.08 | 2023-2025 | |
| Seagen INC. | $194.18 | 2021-2023 | Tukysa |
| Merck Sharp & Dohme LLC | $171.62 | 2021-2023 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $167.37 | 2021-2024 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $82.25 | 2021-2022 | |
| Janssen Biotech, INC. | $60.18 | 2022-2023 | Erleada |
| Eisai INC. | $45.65 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $43.89 | 2021-2022 | |
| Stemline Therapeutics INC. | $20.00 | 2024 | Orserdu |
| Emd Serono, INC. | $18.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Seidman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.